Inside the research
Quest Diagnostics Incorporated
DGX Research profile · latest available data
Price overview
$236.32
▼ -0.27 (-0.1%)
| 52w hi | $247.45 |
|---|---|
| 52w lo | $171.25 |
| Vol | 741.70K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.55
| Short | +0.48 |
|---|---|
| Medium | +0.68 |
| Long | +0.45 |
computed 2026-09-27
Key fundamentals
Quest Diagnostics Incorporated
Healthcare · Diagnostics & Research
| Market cap | $26.08B |
|---|---|
| Enterprise value | $32.24B |
| Trailing P/E | 25.09x |
| Forward P/E | 19.60x |
| EV / EBITDA | 14.23x |
| P / S (ttm) | 2.26x |
| Profit margin | 9.2% |
| Return on equity | 14.6% |
| Revenue growth | +10.2% |
| Earnings growth | +15.0% |
| Debt / equity | 81.07 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.25 | |
| Sector | +0.08 | |
| Technical | +0.39 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Risk Metrics
| Beta vs SPX | 0.15 |
|---|---|
| Corr SPX | 0.10 |
| Annual vol | 23.5% |
| Annual ret | +24.5% |
| Sharpe | 1.04 |
| Max DD | -11.9% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $223.25 |
|---|---|
| High / Low | $245.00 / $184.00 |
| Median | $225.00 |
| Analysts | 16 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 7 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-22 | UBS | → Neutral |
| 2026-04-22 | Truist Securities | → Hold |
| 2026-04-22 | Barclays | → Overweight |
| 2026-04-22 | Baird | → Neutral |
| 2026-04-08 | Evercore ISI Group | → In-Line |
| 2026-02-12 | Mizuho | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-23 | Earnings Release, Exhibits | read |
| 2026-05-21 | Shareholder Vote | read |
| 2026-05-08 | Material Agreement, Exhibits | read |
| 2026-05-01 | Other Material Event, Exhibits | read |
| 2026-04-21 | Earnings Release, Exhibits | read |
| 2026-03-12 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-10 | Earnings Release, Other Material Event… | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-21 | Earnings Release, Exhibits | read |
| 2025-07-22 | Earnings Release, Exhibits | read |
| 2025-05-22 | Shareholder Vote | read |
| 2025-04-22 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-28 | DELANEY MARK E | SVP & Chief Commercial Of | Sell | 1.60K | $376.29K |
| 2026-07-22 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 37 | $7.65K |
| 2026-07-22 | CARTER ROBERT B | L | 11 | $2.27K | |
| 2026-07-22 | Gregg Vicky B | Grant | 72 | $14.89K | |
| 2026-07-22 | Plewman Patrick | SVP for Diagnostic Servic | L | 46 | $9.51K |
| 2026-07-22 | MAIN TIMOTHY L | L | 21 | $4.34K | |
| 2026-07-22 | SAMAD SAM | Executive Vice President | Grant | 102 | $21.09K |
| 2026-07-22 | Lassiter Wright III | L | 6 | $1.24K | |
| 2026-07-22 | DELANEY MARK E | SVP & Chief Commercial Of | L | 34 | $7.03K |
Flow & Concentration
| Insider 180d net | -$376.29K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
Dividends
| Yield (TTM) | 1.04% |
|---|---|
| $ / share (TTM) | $2.46 |
| 5y CAGR | +7.3% |
Annual dividend per share
| 2021 | $2.42 |
|---|---|
| 2022 | $2.60 |
| 2023 | $2.79 |
| 2024 | $2.96 |
| 2025 | $3.15 |
| 2026 | $1.66 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $11.04B | +2.7% | |
| Gross profit | $552.00M | -3.6% | |
| Operating income | $1.26B | +0.2% | |
| Net income | $854.00M | +1.0% | |
| Cash from ops | $1.33B | +2.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $236.37 | $238.25 | $235.48 | $236.32 | 741.70K |
| Sep 24 | $234.08 | $237.29 | $233.55 | $236.59 | 926.90K |
| Sep 23 | $235.12 | $238.62 | $231.92 | $233.00 | 1.13M |
| Sep 22 | $228.59 | $237.29 | $227.24 | $234.76 | 2.72M |
| Sep 21 | $247.13 | $248.84 | $243.93 | $244.88 | 907.60K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →